## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-2.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($56.02)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Here’s Why BioTechne (TECH) Traded Lower in Q3**
- Source: Insider Monkey | 20251211T144304 | Neutral | Relevance: 99%
-  Mairs & Power Balanced Fund highlighted Bio-Techne Corporation (NASDAQ:TECH) in its Q3 2025 investor letter, noting the stock's underperformance due to uncertainties in biopharmaceutical funding. Despite the recent weakness, the fund has increased its holdings in Bio-Techne, a company that develops and sells life science reagents and services. The article also notes that Bio-Techne's revenues in Q1 2026 were down 1% year-over-year.

**2. Bio-Techne (NASDAQ: TECH) and Wyss Geneva to develop automated 3D multiomics workflow**
- Source: Stock Titan | 20251211T120930 | Bullish | Relevance: 99%
-  Bio-Techne and the Wyss Center Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D tissue specimens. This partnership aims to extend Bio-Techne's multiomic spatial biology capabilities from 2D to 3D samples, enabling high-resolution analysis and overcoming manual process limitations. The initiative is expected to accelerate drug discovery, enhance diagnostic development, and potentially reduce animal testing by advancing organoid research and AI-driven predictive modeling.

**3. Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis**
- Source: Investing News Network | 20251209T120903 | Bullish | Relevance: 99%
-  Bio-Techne Corporation has launched its enhanced Leo System, powered by Simple Western Technology, which introduces dual-channel fluorescence detection alongside chemiluminescence for advanced protein analysis. This system offers expanded multiplexing capabilities, enabling researchers to quantify multiple targets simultaneously and process up to 100 capillaries within three hours. The new Leo System aims to provide unmatched precision and efficiency for clinical research and drug discovery, supporting 21 CFR Part 11 compliance.

**4. Bio-Techne (NASDAQ: TECH) debuts Leo system with dual-channel fluorescence**
- Source: Stock Titan | 20251209T113222 | Somewhat-Bullish | Relevance: 98%
-  Bio-Techne (NASDAQ: TECH) has launched its enhanced Leo System, an upgraded Simple Western platform. This system integrates chemiluminescence with dual-channel near-infrared and infrared fluorescence, significantly expanding its multiplexing capabilities for protein analysis. Key features include the ability to quantify up to 24 targets per sample, process 100 capillaries in three hours with reported 5–6% variability, and support 21 CFR Part 11 compliance.

**5. Bio-techne and Wyss Center partner to develop automated 3D multiomics**
- Source: Investing.com Canada | 20251211T115130 | Somewhat-Bullish | Relevance: 98%
-  Bio-Techne Corporation has announced a strategic collaboration with the Wyss Center for Bio and Neuroengineering to develop an automated workflow for 3D multiomic analysis of RNA and protein in tissue specimens. This partnership aims to enhance spatial insights in biology, accelerate drug discovery by reducing reliance on animal models, and advance organoid research and AI-driven predictive modeling by extending Bio-Techne's existing 2D multiomic capabilities into three dimensions. The company, which maintains solid financial health despite recent stock fluctuations, reported over $1.2 billion in net sales in fiscal 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 27.5x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.4B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 27.5 |
| Current P/E | 30.5 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -1.5% to -4.0% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.09x) but short-term weakness (below SMA20). RSI neutral at 47.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.04% (CS: 16) | Weak |
| RSI_14 | 46.7 | Neutral |
| MACD Histogram | -0.39 | Bearish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 1.088x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $60.26
- **Stop Loss:** $56.02 (7.0% risk)
- **Target:** $68.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 325
- **Position Value:** $19,584.50
- **Portfolio %:** 19.58%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*